(Q38150670)

29 August 2017

title

New therapeutic avenues in ulcerative colitis: thinking out of the box. (English)

1 reference

29 August 2017

1 reference

Jean-Frédéric Colombel

series ordinal

3

object named as

Jean-Frédéric Colombel

1 reference

29 August 2017

2

Silvio Danese

1 reference

29 August 2017

Joana Torres

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 November 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

62

1 reference

29 August 2017

issue

11

1 reference

29 August 2017

page(s)

1642-1652

1 reference

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Ulcerative colitis in the Tuzla region of Bosnia and Herzegovina between 1995 and 2006: epidemiological and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

How expensive is inflammatory bowel disease? A critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Decreasing colectomy rates for ulcerative colitis: a population-based time trend study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

New therapies for inflammatory bowel disease: from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Anti-adhesion molecule therapy for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Risk of tuberculosis reactivation with tofacitinib (CP-690550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Anti-inflammatory effects of phosphatidylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Lipid based therapy for ulcerative colitis-modulation of intestinal mucus membrane phospholipids as a tool to influence inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression is downregulated in patients with active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

PPARgamma as a new therapeutic target in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Revisiting the rosiglitazone story--lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Signal integration in the endoplasmic reticulum unfolded protein response

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Endoplasmic reticulum stress: implications for inflammatory bowel disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Altered endoplasmic reticulum stress affects translation in inactive colon tissue from patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

21 January 2018

Hypoxia and inflammation

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

The function of our microbiota: who is out there and what do they do?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Gastrointestinal microbiology enters the metagenomics era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Phylogenetic analysis of dysbiosis in ulcerative colitis during remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Treating Clostridium difficile infection with fecal microbiota transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Fecal microbiota transplantation--an old therapy comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Duodenal infusion of donor feces for recurrent Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Fecal bacteriotherapy for ulcerative colitis: patients are ready, are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Association between parasite infection and immune responses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Trichuris suis therapy in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Helminth antigen-based strategy to ameliorate inflammation in an experimental model of colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Alteration of the murine gut microbiota during infection with the parasitic helminth Heligmosomoides polygyrus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Trichuris suis-induced modulation of human dendritic cell function is glycan-mediated.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Colonization with Heligmosomoides polygyrus suppresses mucosal IL-17 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Helminthic therapy: using worms to treat immune-mediated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Use of attenuated bacteria as delivery vectors for DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Therapeutic potential of human elafin

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Drug discovery from medicinal plants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Andrographis paniculata extract (HMPL-004) for active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Finding new tricks for old drugs: an efficient route for public-sector drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Discovery and preclinical validation of drug indications using compendia of public gene expression data

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Nanomedicine: application areas and development prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Nanomedicine: current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

The 10 remaining mysteries of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation--a single-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Bile salts and cholestasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

The bile acid receptor FXR is a modulator of intestinal innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-gamma-STAT-1 pathway in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

A meta-analysis of the role of smoking in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Impact of cessation of smoking on the course of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Endoplasmic reticulum stress induced by aqueous extracts of cigarette smoke in 3T3 cells activates the unfolded-protein-response-dependent PERK pathway of cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Appendectomy and protection against ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Appendicectomy as a therapy for ulcerative proctitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Appendix is a priming site in the development of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Local appendiceal dysbiosis: the missing link between the appendix and ulcerative colitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Potential Danger in the Medical Use of Trichuris suis for the Treatment of Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303959

A role for proteinase-activated receptor-1 in inflammatory bowel diseases

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1172/JCI21689

Identifiers

DOI

10.1136/GUTJNL-2012-303959

1 reference

release_ffulm2ta3jfcnck5nshaoquglq

29 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ffulm2ta3jfcnck5nshaoquglq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference